1,1,1-trifluoropentan-2-amine | 1335661-17-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1,1,1-trifluoropentan-2-amine
• 英文别名: (S)-1,1,1-Trifluoro-2-pentylamine；(2S)-1,1,1-trifluoropentan-2-amine
• CAS: 1335661-17-0
• 化学式: C₅H₁₀F₃N
• 分子量: 141.136
• InChiKey: YFKRQARROWXYNI-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 1,1,1-trifluoropentan-2-amine 在 盐酸 、 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group

  摘要：

  Although all kinases share the same ATP binding pocket, subtle differences in the residues that form the pocket differentiate individual kinases' affinity for ATP competitive inhibitors. We have found that by introducing a single methyl group, the selectivity of our MERTK inhibitors over another target, FLT3, was increased up to 1000-fold (compound 31). Compound 19 was identified as an in vivo tool compound with subnanomolar activity against MERTK and 38-fold selectivity over FLT3 in vitro. The potency and selectivity of 19 for MERTK over FLT3 were confirmed in cell-based assays using human cancer cell lines. Compound 19 had favorable pharmacokinetic properties in mice. Phosphorylation of MERTK was decreased by 75% in bone marrow leukemia cells from mice treated with 19 compared to vehicle-treated mice.

  DOI：

  10.1021/acs.jmedchem.8b01229

文献信息

• Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group
  作者：Jichen Zhao、Dehui Zhang、Weihe Zhang、Michael A. Stashko、Deborah DeRyckere、Eleana Vasileiadi、Rebecca E. Parker、Debra Hunter、Qingyang Liu、Yuewei Zhang、Jacqueline Norris-Drouin、Bing Li、David H. Drewry、Dmitri Kireev、Douglas K. Graham、Henry Shelton Earp、Stephen V. Frye、Xiaodong Wang

  DOI：10.1021/acs.jmedchem.8b01229

  日期：2018.11.21

  Although all kinases share the same ATP binding pocket, subtle differences in the residues that form the pocket differentiate individual kinases' affinity for ATP competitive inhibitors. We have found that by introducing a single methyl group, the selectivity of our MERTK inhibitors over another target, FLT3, was increased up to 1000-fold (compound 31). Compound 19 was identified as an in vivo tool compound with subnanomolar activity against MERTK and 38-fold selectivity over FLT3 in vitro. The potency and selectivity of 19 for MERTK over FLT3 were confirmed in cell-based assays using human cancer cell lines. Compound 19 had favorable pharmacokinetic properties in mice. Phosphorylation of MERTK was decreased by 75% in bone marrow leukemia cells from mice treated with 19 compared to vehicle-treated mice.